Adrien Costantini

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Adrien Costantini, Catherine Julié, Coraline Duménil et al. · OncoImmunology · 2018 · 173 citations · Full text

Medicine, Immunology, Oncology +17

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Ali Chour, Julie Denis, Céline Mascaux et al. · Journal of Thoracic Oncology · 2023 · 72 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression

Etienne Giroux‐Leprieur, Zofia Hélias‐Rodzewicz, Paul Takam Kamga et al. · Journal for ImmunoTherapy of Cancer · 2020 · 37 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

Adrien Costantini, Jennifer Corny, Vincent Fallet et al. · ERJ Open Research · 2018 · 26 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer

Camille Mehlman, Paul Takam Kamga, Adrien Costantini et al. · Cancers · 2021 · 25 citations · Full text

Life Sciences, Cancer Biology, Oncology +17